Black Diamond Therapeutics, Inc. (BDTX)

Several events influenced Black Diamond Therapeutics' stock price over the past six months. The company reported a narrowed net loss for Q2 2025 and completed enrollment for its Phase 2 silevertinib trial on August 7, 2025. In Q3 2025, the company reported a net loss of $8.5 million, but maintained a strong cash position. Black Diamond Therapeutics participated in investor conferences in November and December 2025. The stock experienced fluctuations, including a gain of 4.40% on February 6, 2026. A critical upcoming catalyst for the stock is the expected readout of objective response rate (ORR) and preliminary duration of response (DOR) data from the Phase 2 silevertinib trial in Q4 2025.

As a clinical-stage biotechnology company, Black Diamond Therapeutics, Inc. has no discernible demand seasonality for its products or services, as its products are not yet commercialized. The company's revenue model relies on strategic collaborations and licensing agreements rather than product sales.

Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage oncology company focused on developing "MasterKey" therapies targeting families of oncogenic mutations in cancer patients. Their approach addresses genetically defined tumors, overcomes treatment resistance, minimizes toxicities, and achieves brain penetrance. The primary product candidate is silevertinib (BDTX-1535), a brain-penetrant EGFR MasterKey inhibitor in Phase 2 trials for EGFR-mutant NSCLC and GBM. BDTX-4933, a RAF/RAS-mutant solid tumor therapy, was out-licensed to Servier Pharmaceuticals LLC in March 2025.

Black Diamond Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, USA, a biotechnology innovation hub.

Black Diamond Therapeutics' brand reputation is tied to its scientific advancements, clinical pipeline progress, and financial stewardship. The company has focused on silevertinib and extended its cash runway through cost reductions and a licensing deal. The completion of enrollment for its Phase 2 silevertinib trial and the anticipation of key clinical data in Q4 2025 are positive indicators.

Black Diamond Therapeutics, Inc.'s ownership is predominantly held by institutional investors, including T. Rowe Price Investment Management, Inc., Vestal Point Capital, LP, NEA Management Company, LLC, Vanguard Group Inc, Tang Capital Management Llc, and Marshall Wace, Llp. The largest individual shareholder is Ali Behbahani, who holds a substantial stake of 15.79% of the company.